notabl chang execut comp
event chang control cic
what new file day ago upon within month follow
chang control compani key execut receiv
continu base salari period three year follow termin
employ three time averag annual bonu paid preced
three year amount vari execut see pg prior new abc
jan proxi last year state provid cash sever enhanc
benefit name execut offic sole connect cic abc new
compens relat cic increment prior term type comp
chang event cic could occur variou reason compani
state employ agreement amend restat align sever
cic benefit gener market practic relat peer group
two instanc healthcar servic industri recent year compani
increas sever payment top execut event cic see
compani acquir month later pss world medic prior acquisit
omnicar prior acquisit see pg
pharmedium news pharmedium layoff memphi earlier week trim
ep news may signal delay re-
open facil color pg despit brand inflat bad
fear earli continu leverag strong relationship
rais pt slightli higher price-to-earnings ep
recal earli wall street journal articl suggest
walgreen /ew discuss potenti fulli acquir
discuss prior research separ path hc servic
updat analysi pg valuat
cite relationship key reason premium price-to-earnings vs drug distributor peer
quarterli annual ep usd
consensu number thomson reuter receiv gmt
barclay capit inc and/or one affili seek busi
compani cover research report result investor awar
firm may conflict interest could affect object report investor
consid report singl factor make invest decis
rais usd
return equiti ttm
link barclay live interact chart
equal weight gain
share via largest custom walgreen
compani continu face headwind throughout
relat gener price deflat
believ persist hamper ep growth
upsid case see modest multipl expans
gener price deflat come better fear
would lead improv ep
downsid case see continu persist
gener deflat continu problem
pharmedium bring compani peer
group
margin return data
balanc sheet cash flow mn
equival
short long-term debt
chang work capit
flow oper
valuat leverag metric
languag abc file
follow three paragraph languag directli disclos abc file
januari compani enter amend restat employ
agreement current name execut offic steven colli chairman presid
chief execut offic john chou execut vice presid chief legal
busi offic jame cleari jr execut vice presid chief offic
robert mauch execut vice presid group presid
distribut strateg global sourc upon recommend compani
independ compens consult approv compens success
plan committe board director compani employ
agreement amend restat align sever chang control
benefit gener market practic support benchmark among compani
ceo compens chang event chang control cic
mr colli employ agreement amend provid event mr colli
employ termin compani without caus mr colli good reason
either case upon within month follow chang control compani
provid mr colli deliv effect releas favor compani
affili mr colli receiv follow payment continu base salari
period three year follow termin employ three time averag
annual bonu paid mr colli preced three year paid three substanti
equal instal three-year period follow termin employ
cfo evp compens chang event chang control cic
messr cleari mauch employ agreement amend provid
addit sever would receiv termin employ
compani without caus execut good reason subject deliveri
effect releas favor compani affili termin occur
upon within month follow chang control compani execut
receiv two time averag annual bonus receiv preced three year
paid regular payrol instal two-year period follow termin
employ amend consist amend made employ
agreement execut offic messr colli chou whose
employ agreement alreadi includ benefit
hc servic exampl compens chang cic situat
regard chang control updat prior potenti activ two
exampl situat awar within healthcar servic
recent transact see updat chang control merger omnicar
acquir omnicar may juli compani updat chang
control term execut leadership team exampl awar
acquir pss medic pss medic amend employ
agreement execut chang control juli acquisit pss
medic announc octob
revisit prior hypothet walgreens/abc merger accret analysi
discuss pg conduct initi coverag report
march detail accret analysi full merger two
compani figur provid updat view today month later
hypothet acquisit walgreen remain stake would
own stock back march own closer today
updat analysi assum slightli lower bln takeout price
alleg takeout price first postul wall street journal includ
wba current ownership stake collect repres premium abc
recent share price new analysi see split debt share
issuanc acquir hypothet acquisit would yield accret
rang rel unchang previou analysi accret
hypothet full acquisit walgreen
 hypothet acquisit bil revenu excl ebit excl /rad growth margin oper synergi incl mln/yr inter-company distribut fee ebit increment interest foregon interest debt total increment interest/loss equiti pre-tax incom stand-alone pre-tax incom excl combin compani pre-tax growthnew combin combin compani adj net stand-alone ep excl equiti combin compani growth ep accret dilut excl current fulli dilut share foregon share buyback issu compani fulli dilut barclay corp
updat pharmedium oper
earlier week report abc pharmedium unit file warn notic
unit would lay worker memphi facil march come
employe facil retain recal facil voluntarili shut
dec due qualiti issu compani believ
track re-open facil throughout compani yet receiv all-clear
fda addit commit re-open facil fda
provid feedback given uncertainti regard exact time re-open
facil compani guidanc assum three scenario
pharmedium busi tailwind profit flat y/i pharmedium
signific headwind
recent announc layoff memphi facil believ
facil less like re-open abc time abc guidanc
assum pharmedium would flat profit perspect y/i basi middl
scenario given layoff uncertainti facil may re-open
trim ep low end
compani guidanc see pharmedium busi
signific headwind per rather flat y/i reduct ep reduc
ep background pharmedium pleas see
prior research deeper dive pharmedium
growthmid singl digit oper expens growthmid singl digit growthdistribut servic op profit growthlow mid singl digit growthoth op profit growthhigh singl digit growthoper profit growthlow mid singl digit interest y/yadj effect tax changebrand inflationmid-singl digit inflationgener deflationsimilar tail end stabl nowshar ep y/i barclay corp
amerisourcebergen revenu profit model
 annual revenu model mil abcabcabcabcrevenu revenueabdc drug specialti distribut global commerci servic anim growthabdc drug specialti distribut global commerci servic anim total revsabdc drug specialti distribut global commerci servic anim annual gross profit mil abcabcabcabcgross profit gross profit formula pharma distribut strateg global global commerci servic anim incom gross growthpharma distribut strateg global global commerci servic anim incom charg nmnmnmnmnmnmnmnmtotal gross gp margin press releas pharma distribut strateg global global commerci servic anim incom charg nmnmnmnmnmnmnmnmtotal gross profit annual oper profit mil abcabcabcabcoper profit ebit ebitpharma distribut strateg global global commerci servic anim incom growthpharma distribut strateg global global commerci servic anim incom charg nmnmnmnmnmnmnmnmtotal ebit barclay corp
 quarterli incom statement mil ep ep ep distribut sell oper addback check excl intang asset ens rate check ep fulli dilut share growth distribut sell per barclay corp
 annual revenu model mil abcabcabcrevenu revenueabdc drug specialti distribut global commerci servic anim growthabdc drug specialti distribut global commerci servic anim total revsabdc drug specialti distribut global commerci servic anim annual gross profit mil abcabcabcgross profit gross profit formula pharma distribut strateg global global commerci servic anim incom gross growthpharma distribut strateg global global commerci servic anim incom charg nmnmnmnmnmnmtotal gross gp margin press releas pharma distribut strateg global global commerci servic anim incom charg nmnmnmnmnmnmtotal gross profit annual oper profit mil abcabcabcoper profit ebit ebitpharma distribut strateg global global commerci servic anim incom growthpharma distribut strateg global global commerci servic anim incom charg nmnmnmnmnmnmtotal ebit barclay corp
 annual incom statement distribut sell oper addback check excl intang asset ens rate interest ens check ep fulli dilut share growth distribut sell per barclay corp
steve valiquett herebi certifi view express research report accur reflect person view
subject secur issuer refer research report part compens directli indirectli relat
specif recommend view express research report
barclay research produc invest bank barclay bank plc affili collect individu barclay
author contribut research report research analyst unless otherwis indic public date top report
reflect local time report produc may differ releas date provid gmt
avail disclosur
compani subject research report current import disclosur regard compani pleas refer
